Vanguard Group Inc. Has $57.33 Million Stock Holdings in MBX Biosciences, Inc. $MBX

Vanguard Group Inc. boosted its position in MBX Biosciences, Inc. (NASDAQ:MBX) by 8.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,817,811 shares of the company’s stock after purchasing an additional 140,449 shares during the quarter. Vanguard Group Inc.’s holdings in MBX Biosciences were worth $57,334,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in MBX Biosciences in the 4th quarter valued at approximately $28,000. Russell Investments Group Ltd. raised its position in MBX Biosciences by 4,131.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after buying an additional 1,446 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in MBX Biosciences in the 3rd quarter valued at approximately $27,000. CWM LLC raised its position in MBX Biosciences by 28.9% in the 4th quarter. CWM LLC now owns 1,784 shares of the company’s stock valued at $56,000 after buying an additional 400 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in MBX Biosciences in the 4th quarter valued at approximately $69,000.

MBX Biosciences Stock Down 8.2%

NASDAQ:MBX opened at $32.45 on Friday. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -14.68 and a beta of 0.78. MBX Biosciences, Inc. has a twelve month low of $9.43 and a twelve month high of $45.85. The stock’s 50 day moving average price is $31.48 and its two-hundred day moving average price is $31.84.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.15. As a group, analysts anticipate that MBX Biosciences, Inc. will post -2.84 earnings per share for the current year.

Insider Activity at MBX Biosciences

In other MBX Biosciences news, CEO P. Kent Hawryluk bought 18,500 shares of MBX Biosciences stock in a transaction dated Friday, March 13th. The stock was bought at an average cost of $28.41 per share, for a total transaction of $525,585.00. Following the purchase, the chief executive officer owned 486,777 shares of the company’s stock, valued at $13,829,334.57. The trade was a 3.95% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 52.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Wall Street Zen raised MBX Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Citigroup reaffirmed an “outperform” rating on shares of MBX Biosciences in a research report on Tuesday. Citizens Jmp boosted their price target on MBX Biosciences from $76.00 to $86.00 and gave the stock a “market outperform” rating in a research report on Tuesday. Stifel Nicolaus set a $56.00 price target on MBX Biosciences in a research report on Tuesday. Finally, TD Cowen reaffirmed a “buy” rating on shares of MBX Biosciences in a research report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, MBX Biosciences has an average rating of “Moderate Buy” and a consensus price target of $60.22.

MBX Biosciences Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.